| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Suberol functions as a peptide synthesis reagent rather than a drug with a pharmacological target. Its primary application is in solid-phase peptide synthesis (SPPS) as an acid-labile linker for the preparation of peptide amides. The Fmoc group serves as a temporary protecting group for the amino functionality, which can be removed under mild basic conditions (typically piperidine in DMF). The dibenzocycloheptene core provides the acid-labile linkage that allows cleavage of the peptide amide from the resin under acidic conditions.
|
|---|---|
| ln Vitro |
In vitro activity is not applicable for Fmoc-Suberol as it is a chemical reagent for peptide synthesis rather than a biologically active compound. Its "activity" is assessed by its performance in peptide synthesis, including coupling efficiency, cleavage yield, and purity of the resulting peptide amides. The compound is evaluated for its ability to facilitate the synthesis of peptide amides with high yield and purity.
|
| ln Vivo |
In vivo activity is not applicable for Fmoc-Suberol as it is a peptide synthesis reagent and not a therapeutic compound. The compound is used exclusively in laboratory settings for chemical synthesis and is not administered to animals or humans. Its applications are limited to in vitro peptide synthesis and protein cross-linking research.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for Fmoc-Suberol as it is a chemical reagent with no known biological targets. The compound's utility is assessed through standard peptide synthesis protocols where it functions as a solid-phase linker. Quality control assays include HPLC analysis to confirm purity (typically ≥95%) and NMR spectroscopy to verify structural integrity. Coupling efficiency is evaluated by monitoring Fmoc deprotection and peptide chain elongation.
|
| Cell Assay |
In vitro cellular assays are not applicable for Fmoc-Suberol as it is a peptide synthesis reagent with no biological activity. The compound is used in chemical synthesis laboratories rather than cell culture applications. Standard handling involves dissolution in appropriate organic solvents (e.g., DMF, DCM) for peptide synthesis applications. The compound is stored at 2-8°C under refrigeration.
|
| Animal Protocol |
In vivo animal studies are not applicable for Fmoc-Suberol as it is a chemical reagent for peptide synthesis and not a therapeutic compound. No animal studies are performed with this compound for therapeutic evaluation. The compound is used exclusively in laboratory settings for chemical synthesis and is not intended for administration to animals or humans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for Fmoc-Suberol as it is a peptide synthesis reagent and not a therapeutic compound. The compound is not designed for oral or systemic administration. Its physical properties include a melting point of 225-233°C, density of 1.4, and refractive index of 1.69. The compound is a solid powder at room temperature and is stored under refrigeration at 2-8°C.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Fmoc-Suberol are limited in the published literature. As a peptide synthesis reagent, standard laboratory safety precautions should be followed when handling the compound. The compound is not intended for human or veterinary use. Material safety data sheet (MSDS) information should be consulted for detailed hazard information. The compound should be handled with appropriate personal protective equipment in a well-ventilated fume hood.
|
| References |
[1]. M. Noda, et al. Facile synthesis of the acid-labile peptide amide linker containing the 10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl group. Peptide Science-Present and Future pp 516–518.
|
| Additional Infomation |
Fmoc-Suberol (Ramage Linker) is a specialized reagent used in solid-phase peptide synthesis for the preparation of peptide amides. It features an Fmoc protecting group and an acid-labile dibenzocycloheptene core. The compound is supplied at ≥95% purity and is stored at 2-8°C. It is not a drug and has no therapeutic applications; it is used exclusively as a research chemical in peptide synthesis and protein cross-linking research.
|
| Molecular Formula |
C32H27NO5
|
|---|---|
| Molecular Weight |
505.56
|
| Exact Mass |
505.188
|
| CAS # |
212783-75-0
|
| PubChem CID |
10553577
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
724.1±60.0 °C at 760 mmHg
|
| Flash Point |
391.7±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
6.82
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
811
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])C([H])([H])C2C([H])=C(C([H])=C([H])C1=2)OC([H])([H])C(=O)O[H])=O)C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
XHOBPBDZGGKEOX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H27NO5/c34-30(35)19-37-22-15-16-24-21(17-22)14-13-20-7-1-2-8-23(20)31(24)33-32(36)38-18-29-27-11-5-3-9-25(27)26-10-4-6-12-28(26)29/h1-12,15-17,29,31H,13-14,18-19H2,(H,33,36)(H,34,35)
|
| Chemical Name |
2-[[2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl]oxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9780 mL | 9.8900 mL | 19.7800 mL | |
| 5 mM | 0.3956 mL | 1.9780 mL | 3.9560 mL | |
| 10 mM | 0.1978 mL | 0.9890 mL | 1.9780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
